SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-076613
Filing Date
2024-03-25
Accepted
2024-03-25 17:04:05
Documents
19
Period of Report
2024-03-21
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d816036d8k.htm   iXBRL 8-K 32931
2 EX-4.1 d816036dex41.htm EX-4.1 91752
3 EX-4.2 d816036dex42.htm EX-4.2 95651
4 EX-5.1 d816036dex51.htm EX-5.1 14390
5 EX-10.1 d816036dex101.htm EX-10.1 178507
6 EX-10.2 d816036dex102.htm EX-10.2 183359
10 GRAPHIC g816036g77j47.jpg GRAPHIC 30526
  Complete submission text file 0001193125-24-076613.txt   915365

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA sgmo-20240321.xsd EX-101.SCH 2850
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE sgmo-20240321_lab.xml EX-101.LAB 17235
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sgmo-20240321_pre.xml EX-101.PRE 10812
23 EXTRACTED XBRL INSTANCE DOCUMENT d816036d8k_htm.xml XML 3534
Mailing Address 501 CANAL BLVD. RICHMOND CA 94084
Business Address 501 CANAL BLVD. RICHMOND CA 94084 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

IRS No.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-30171 | Film No.: 24780040
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)